share_log

藥師幫：截至2023年12月31日止年度年度業績公告

YSB: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2023

Hong Kong Stock Exchange ·  Mar 11 08:51
Summary by Moomoo AI
藥師幫股份有限公司（「本公司」）公佈截至2023年12月31日止年度的年度業績。本集團收入達人民幣約169.72億元，較去年同期增長18.9%。自營業務收入為人民幣約160.36億元，平台業務收入為人民幣約8.73億元，其他業務收入為人民幣約6291萬元。毛利增至人民幣約17.41億元，增長21.3%。年內虧損則擴大至人民幣約32.07億元，較去年同期的虧損增加113.8%。非國際財務報告準則下，經調整淨利潤為人民幣約1.31億元。總GMV達人民幣約469.12億元，同比增長24.0%。本公司於2023年成功登陸香港資本市場，並持續推動院外醫藥市場的創新和發展，提升行業效率。報告期內，本集團並無派發任何股息。
藥師幫股份有限公司（「本公司」）公佈截至2023年12月31日止年度的年度業績。本集團收入達人民幣約169.72億元，較去年同期增長18.9%。自營業務收入為人民幣約160.36億元，平台業務收入為人民幣約8.73億元，其他業務收入為人民幣約6291萬元。毛利增至人民幣約17.41億元，增長21.3%。年內虧損則擴大至人民幣約32.07億元，較去年同期的虧損增加113.8%。非國際財務報告準則下，經調整淨利潤為人民幣約1.31億元。總GMV達人民幣約469.12億元，同比增長24.0%。本公司於2023年成功登陸香港資本市場，並持續推動院外醫藥市場的創新和發展，提升行業效率。報告期內，本集團並無派發任何股息。
Drugstore Co., Ltd. (the “Company”) announces its annual results for the year ended 31 December 2023. The Group's revenue reached approximately RMB169.72 billion, an increase of 18.9% year-on-year. The revenue of self-employed business is about RMB160.36 billion, platform business revenue is RMB8.73 million, and other business income is RMB6291 million. Gross profit increased to approximately RMB17.41 billion, an increase of 21.3%. The year-on-year loss widened to approximately RMB 32.7 billion, an increase of 113.8% from the same period last year. Adjusted net profit was approximately RMB1.31 million under non-international financial reporting criteria. Total GMV reached RMB469.12 billion, up 24.0% year-on-year. The Company successfully entered the Hong Kong capital market in 2023 and continues to drive innovation and development in the out-of-hospital medical market to improve the efficiency of the industry. DURING THE REPORTING PERIOD, THE GROUP DID NOT DISTRIBUTE ANY DIVIDENDS.
Drugstore Co., Ltd. (the “Company”) announces its annual results for the year ended 31 December 2023. The Group's revenue reached approximately RMB169.72 billion, an increase of 18.9% year-on-year. The revenue of self-employed business is about RMB160.36 billion, platform business revenue is RMB8.73 million, and other business income is RMB6291 million. Gross profit increased to approximately RMB17.41 billion, an increase of 21.3%. The year-on-year loss widened to approximately RMB 32.7 billion, an increase of 113.8% from the same period last year. Adjusted net profit was approximately RMB1.31 million under non-international financial reporting criteria. Total GMV reached RMB469.12 billion, up 24.0% year-on-year. The Company successfully entered the Hong Kong capital market in 2023 and continues to drive innovation and development in the out-of-hospital medical market to improve the efficiency of the industry. DURING THE REPORTING PERIOD, THE GROUP DID NOT DISTRIBUTE ANY DIVIDENDS.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more